Krebs Biochemicals reported a revenue of INR 23.7 crore in FY26, but posted a loss before tax of INR 16.9 crore. The Vizag production unit remains shut due to pollution control orders, while an audit report confirms the company's financial accuracy.

Krebs Biochemicals has scheduled a board meeting on May 21, 2026, to approve the audited results for their fiscal year 2026. The trading window will be closed from March 31, 2026, until 48 hours after the results are declared.